Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Clin Exp Gastroenterol ; 17: 191-200, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-39050122

RESUMO

Background and Objectives: The success rate of Helicobacter pylori (H. pylori) eradication in China is declining. The aim of this study was to evaluate eradication outcomes in clinical practice and identifies factors contributing to treatment failure. Methods: A retrospective review was conducted on patients treated for H. pylori infection with 14-day bismuth-containing quadruple therapy at a Beijing medical center from January 2020 to December 2023. We analyzed demographic and clinical data, eradication rates across regimens, and performed multivariate analysis to pinpoint predictors of failure. Results: Out of 3340 participants, 2273 (68.1%) achieved eradication. Amoxicillin-based combinations (69.2%) outperformed other antibiotic regimens (58.9%, p < 0.001), with amoxicillin plus doxycycline reaching a 71.4% success rate. Esomeprazole-based regimens were more effective (73.6%) than other PPI regimens (65.2%, p = 0.001), notably, a rabeprazole, amoxicillin, doxycycline, and bismuth combination had an 80.0% success rate. Age, gender, and smoking and drinking were significant eradication failure predictors. Conclusion: In real-world settings, 14-day amoxicillin and esomeprazole-based quadruple regimens have been demonstrated to be more effective than other regimens. Age, gender, and lifestyle habits are identified as independent risk factors for eradication failure. Registration: This study was registered in the Chinese Clinical Trial Registry on 08/01/2024 (clinical trial registration number: ChiCTR2400079647).

2.
J Med Virol ; 91(3): 351-360, 2019 03.
Artigo em Inglês | MEDLINE | ID: mdl-30267587

RESUMO

OBJECTIVE: This study was performed to determine the antigenic and genetic characteristics and evaluate potential vaccine efficacy of influenza A (H1N1)pdm09 in Yantai from August 2009 to August 2017. MATERIALS AND METHODS: A total of 10 236 swabs were collected among patients with an influenza-like illness who were admitted to two sentinel surveillance hospitals in Yantai, East China, from August 2009 to August 2017. All specimens were cultured in Madin-Darby canine kidney cells and identified by haemagglutination-inhibition assay. Complete sequences of haemagglutinin (HA) and neuraminidase of 51 influenza A(H1N1)pdm09 strains circulating in Yantai were amplified, sequenced and analysed using molecular and phylogenetic methods. The potential vaccine efficacy was calculated using the p epitope model which measured the antigenic variation based on the changes in the dominant epitope of HA. RESULTS: The results showed that most Yantai strains were grouped into genetic clades 1.7, 6C, 6B.1 and 6B.2. The amino acid substitutions accumulated gradually in HA proteins and considerable genetic variation were observed in circulating A(H1N1)pdm09 viruses during the seven influenza seasons. The V241I, N369K, N386K and K432E mutations which may change the binding pattern and affinity of oseltamivir for neuraminidase were detected in the strains circulating in 2016/2017 and 2017/2018 seasons and the recommended vaccine strains could afford optimal protection against the influenza A/H1N1pdm09. CONCLUSIONS: Although influenza A(H1N1)pdm09 viruses acquired significant genetic variation over the course of seven influenza seasons, the recommended vaccine strains still afforded protection against main circulating strains. Continuous epidemiological and virological surveillance are necessary.


Assuntos
Variação Antigênica , Antígenos Virais/genética , Glicoproteínas de Hemaglutininação de Vírus da Influenza/genética , Vírus da Influenza A Subtipo H1N1/genética , Vírus da Influenza A Subtipo H1N1/imunologia , Influenza Humana/epidemiologia , Substituição de Aminoácidos , Antígenos Virais/imunologia , China/epidemiologia , Epitopos/imunologia , Evolução Molecular , Glicoproteínas de Hemaglutininação de Vírus da Influenza/imunologia , Humanos , Influenza Humana/imunologia , Influenza Humana/prevenção & controle , Filogenia , RNA Viral/genética , Estações do Ano , Vigilância de Evento Sentinela , Potência de Vacina
3.
PLoS One ; 11(7): e0159568, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27454120

RESUMO

Stress granules (SGs) in response to various stresses have been reported in many diseases. We previously reported the implication of programmed cell death 4 (Pdcd4) in obesity-induced stress responses, but the possible link between Pdcd4 and SGs remains lacking. In this study we showed that oxidized low-density lipoprotein (ox-LDL) or high-fat diet (HFD) induced SG formation in mouse macrophages and liver tissues, and Pdcd4 deficiency in mice remarkably reduced its formation. In response to ox-LDL, either endogenous or ectopic Pdcd4 displayed granule-like expression and co-localized with SG markers including T-cell-restricted intracellular antigen-1, fragile X mental retardation-related protein 1, and eukaryotic initiation factor 4A. Ectopic expression of truncated Pdcd4 that depleted specific RNA-binding motif significantly disrupted the SG formation, suggesting the direct involvement of Pdcd4 in ox-LDL-induced SGs through its RNA-binding activity. Additionally, Pdcd4 deficiency drove AKT activation and suppression of eIF2α phosphorylation, thereby contributing to the resistance to ox-LDL or HFD-induced SG formation. Collectively, our data suggest that Pdcd4 as a crucial regulator in SGs induced by ox-LDL or HFD maybe a potential target for mitigating SG-associated stress responses in obesity and related diseases.


Assuntos
Proteínas Reguladoras de Apoptose/genética , Grânulos Citoplasmáticos/metabolismo , Dieta Hiperlipídica , Lipoproteínas LDL/metabolismo , Proteínas de Ligação a RNA/genética , Estresse Fisiológico , Animais , Proteínas Reguladoras de Apoptose/deficiência , Proteínas Reguladoras de Apoptose/metabolismo , Linhagem Celular , Células Cultivadas , Fator de Iniciação 2 em Eucariotos/metabolismo , Humanos , Lipoproteínas LDL/farmacologia , Fígado/metabolismo , Fígado/patologia , Macrófagos/efeitos dos fármacos , Macrófagos/metabolismo , Macrófagos/patologia , Masculino , Camundongos , Camundongos Knockout , Obesidade/genética , Obesidade/metabolismo , Transporte Proteico , Proteínas Proto-Oncogênicas c-akt/metabolismo , Proteínas de Ligação a RNA/metabolismo
4.
Int Immunopharmacol ; 23(2): 609-16, 2014 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-25466269

RESUMO

Agonistic 4-1BB monoclonal antibody (mAb), a promising approach for tumor immunotherapy, has entered clinical trials for some tumors due to its immunostimulatory effects on immune cells. Hypoxia, the hallmark of tumor microenvironment, influences functions of immune cells including dendritic cells (DCs). It remains unestablished whether 4-1BB mAb takes effects on DCs in hypoxic microenvironment. This study aims to examine the role of agonistic 4-1BB mAb in the maturation and functions of murine hypoxic DCs. As expected, hypoxia suppressed the maturation and activation of DCs, as suggested by down-regulation of class II MHC, co-stimulatory molecules and proinflammatory cytokines. These inhibitory effects of hypoxia were partially reversed by triggering 4-1BB on DCs with agonistic mAb, as evidenced by elevated co-stimulatory molecules CD80, CD86, and proinflammatory cytokines such as IL-6, TNF-α. Unexpectedly, the ability of hypoxic DCs to stimulate CD4+T cell proliferation seemed not to be affected by agonistic 4-1BB mAb. These data demonstrate that agonistic 4-1BB mAb partially restores the phenotypic maturation and proinflammatory function of hypoxic DCs, but fails to rescue their ability to stimulate T cell response. Collectively, our study provides evidence on the efficiency of agonistic 4-1BB mAb in hypoxic microenvironment, deserving of further consideration for clinic application.


Assuntos
Anticorpos Monoclonais/farmacologia , Células Dendríticas , Membro 9 da Superfamília de Receptores de Fatores de Necrose Tumoral/imunologia , Animais , Anticorpos Monoclonais/imunologia , Linfócitos T CD4-Positivos/efeitos dos fármacos , Linfócitos T CD4-Positivos/imunologia , Diferenciação Celular/efeitos dos fármacos , Diferenciação Celular/imunologia , Hipóxia Celular/imunologia , Proliferação de Células/efeitos dos fármacos , Proliferação de Células/fisiologia , Células Cultivadas , Citocinas/biossíntese , Citocinas/imunologia , Células Dendríticas/efeitos dos fármacos , Células Dendríticas/imunologia , Células Dendríticas/fisiologia , Dinoprostona/biossíntese , Dinoprostona/imunologia , Feminino , Citometria de Fluxo , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL
5.
PLoS One ; 9(1): e87787, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24498194

RESUMO

Interleukin (IL)-35 is a newly identified immune negative molecule which is secreted by CD4(+)Foxp3(+) T regulatory cells (Tregs) and contributes to their suppressive capacity. Early data have shown that IL-35 inhibits development of several autoimmune diseases. However, the role of IL-35 in atherosclerosis, a lipid-driven chronic inflammatory disease in arterial wall, remains to be investigated. Here, we found that IL-35 was involved in atherosclerosis in apolipoprotein E-deficient (ApoE(-/-)) mice. ApoE(-/-) mice with established atherosclerotic lesion displayed a lower level of IL-35 compared to age-matched wild type C57BL/6 mice without plaque. However, IL-35 expression increased significantly in ApoE(-/-) mice with attenuated plaque. More importantly, we found that modulation of ER stress treated by chemical chaperone, 4-Phenyl butyric acid (PBA) in vivo, mainly upregulated immune negative regulating molecule IL-35, as well as IL-10 and Foxp3, accompanied by increased Tregs. However, no obvious impact on pro-inflammatory molecules such as TNF-α, IFN-γ, IL-17 and IL-23 was observed, which provides new insight into the benefit of ER stress recovery from attenuated plaque. Our results suggest that IL-35 might have a potential value for atherosclerotic therapy.


Assuntos
Apolipoproteínas E/deficiência , Apolipoproteínas E/genética , Estresse do Retículo Endoplasmático/genética , Interleucinas/genética , Regulação para Cima/genética , Animais , Apolipoproteínas E/metabolismo , Aterosclerose/genética , Aterosclerose/metabolismo , Modelos Animais de Doenças , Fatores de Transcrição Forkhead/genética , Fatores de Transcrição Forkhead/metabolismo , Interferon gama/genética , Interferon gama/metabolismo , Interleucinas/metabolismo , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Placa Aterosclerótica/genética , Placa Aterosclerótica/metabolismo , Fator de Necrose Tumoral alfa/genética , Fator de Necrose Tumoral alfa/metabolismo
6.
Diabetes ; 62(12): 4132-43, 2013 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-23990362

RESUMO

Programmed cell death-4 (PDCD4), a selective protein translation inhibitor, has shown proinflammatory effect in some inflammatory diseases, but its roles in obesity remain unestablished. This study aims to investigate the effects of PDCD4 on obesity, inflammation, and insulin resistance. Surprisingly, high-fat diet (HFD)-fed PDCD4-deficient (PDCD4(-/-)) mice exhibited an absolutely lean phenotype together with improved insulin sensitivity. Compared with wild-type obese mice, HFD-fed PDCD4(-/-) mice showed higher energy expenditure, lower epididymal fat weight, and reduced macrophage infiltration inflammatory cytokine secretion in white adipose tissue (WAT). Alleviated hepatic steatosis along with decreased plasma levels of triglyceride and cholesterol was also observed in these mice. Importantly, PDCD4 appeared to disturb lipid metabolism via inhibiting the expression of liver X receptor (LXR)-α, a master modulator of lipid homeostasis, which was elevated in HFD-fed PDCD4(-/-) mice accompanied by upregulation of its target genes and relieved endoplasmic reticulum stress in WAT. These data demonstrate that PDCD4 deficiency protects mice against diet-induced obesity, WAT inflammation, and insulin resistance through restoring the expression of LXR-α, thereby proposing PDCD4 as a potential target for treating obesity-associated diseases.


Assuntos
Tecido Adiposo/metabolismo , Proteínas Reguladoras de Apoptose/metabolismo , Inflamação/metabolismo , Resistência à Insulina/genética , Obesidade/metabolismo , Proteínas de Ligação a RNA/metabolismo , Animais , Proteínas Reguladoras de Apoptose/genética , Colesterol/sangue , Dieta Hiperlipídica , Estresse do Retículo Endoplasmático/genética , Fígado Gorduroso/genética , Fígado Gorduroso/metabolismo , Inflamação/genética , Metabolismo dos Lipídeos/genética , Fígado/metabolismo , Receptores X do Fígado , Camundongos , Camundongos Knockout , Obesidade/genética , Receptores Nucleares Órfãos/genética , Receptores Nucleares Órfãos/metabolismo , Proteínas de Ligação a RNA/genética , Triglicerídeos/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...